Loading…
Employees: 1,137
Size Kwality Pharmaceuticals (KPL.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $401M, the 938th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹3,645 on 6 Nov 2026.
Performance Over six months the shares gained 111.0%, against -15.9% for the median peer and 0.0% for the India market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 37.9% over the last twelve months (peer median +8.6%); the operating margin is 20.8% (peer median -11.8%).
Valuation It trades at 6.8× enterprise value to sales against a peer median of 5.2× (7th most expensive of 18).
Capital Return on invested capital runs 13.9 points above its cost of capital (12.2% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹5.54B | ₹5.03B | ₹3.70B | ₹3.07B | ₹2.51B |
| Revenue growth | — | +36% | +21% | +22% | — |
| Gross profit | ₹1.89B | ₹1.44B | ₹999M | ₹750M | ₹754M |
| EBITDA | ₹1.35B | ₹1.21B | ₹834M | ₹696M | ₹630M |
| Net income | ₹811M | ₹673M | ₹398M | ₹238M | ₹194M |
| Free cash flow | n/a | -₹387M | ₹188M | ₹24.7M | -₹61.7M |
| Capital expenditure | n/a | ₹489M | ₹288M | ₹306M | ₹504M |
| Total debt | n/a | ₹1.31B | ₹1.12B | ₹981M | ₹903M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | KPL.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.0% | -11.1% | 5th highest of 21 |
| 6-month return | +111.0% | -15.9% | highest of 21 |
| Distance from 52-week high | -7.7% | -39.8% | 2nd highest of 21 |
| Revenue growth (TTM) | +37.9% | +8.6% | 6th highest of 18 |
| Operating margin | 20.8% | -11.8% | highest of 18 |
| EV / Sales | 6.8× | 5.2× | 7th most expensive of 18 |
| ROIC minus cost of capital | +13.9 pp | -7.1 pp | 3rd highest of 15 |
| EV / EBITDA | 28.0× | 10.5× | 2nd most expensive of 7 |
| Net debt / EBITDA | 0.9× | -0.2× | 3rd most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kwality Pharmaceuticals KPL.NS | India | $401M | +111% | +38% | 21% | 6.8× | n/a | n/a |
| Hyundai Bioscience 048410.KS | South Korea | $401M | -58% | +78% | -580% | 158.2× | n/a | n/a |
| Guangdong Lifestrong Pharmacy 301111.SZ | China | $401M | -16% | +7% | -2% | 7.9× | n/a | n/a |
| Tuoxin Pharmaceutical 301089.SZ | China | $400M | -22% | +17% | -20% | 5.8× | n/a | n/a |
| JW Pharmaceutical 001060.KS | South Korea | $402M | -28% | +10% | 14% | 0.7× | -16.9% | +7.2% |
| Shandong Sinobioway Biomedicine 002581.SZ | China | $404M | -40% | +91% | -65% | 7.8× | n/a | n/a |
| Zota Health Care ZOTA.NS | India | $395M | -6% | +69% | -16% | 5.8× | n/a | n/a |
| SanBio 4592.T | Japan | $393M | -58% | n/a | n/a | n/a | n/a | n/a |
| Heartseed 219A.T | Japan | $393M | +52% | +197% | 9% | 21.4× | 50.0% | +73.2% |
| Tiansheng Pharmaceutical 002872.SZ | China | $392M | +15% | -1% | -13% | 5.2× | 23.2% | -15.7% |
| Hansa Biopharma HNSA.ST | Sweden | $410M | +39% | -4% | -304% | 23.7× | n/a | n/a |
| Shaanxi Panlong Pharmaceutical 002864.SZ | China | $411M | -13% | -9% | 9% | 1.6× | -0.4% | +11.2% |
| Anhui Sunhere Pharmaceutical Excipients 300452.SZ | China | $412M | -16% | +9% | 19% | 2.4× | -4.5% | +12.1% |
| Jiangxi Synergy Pharmaceutical 300636.SZ | China | $414M | -16% | -2% | 3% | 3.5× | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $386M | +10% | -12% | -140% | 70.7× | n/a | n/a |
| Assembly Biosciences ASMB | United States | $416M | -31% | +125% | -12% | 1.3× | n/a | n/a |
| Relmada Therapeutics RLMD | United States | $416M | -47% | n/a | n/a | n/a | n/a | n/a |
| MapLight Therapeutics MPLT | United States | $385M | -75% | n/a | n/a | n/a | n/a | n/a |
| JCR Pharmaceuticals 4552.T | Japan | $383M | -11% | +3% | -14% | 2.9× | n/a | n/a |
| Dong-A Socio 000640.KS | South Korea | $425M | -11% | +10% | 7% | 0.7× | -8.8% | +12.8% |
| Puma Biotechnology PBYI | United States | $426M | +10% | -3% | 13% | 1.5× | 2.8% | +0.3% |